Is obesity an independent risk factor for clinical decompensation in patients with cirrhosis?
Obesity has a deleterious effect on the natural history of compensated cirrhosis of all etiologies, independent of portal pressure and liver function. Weight reduction may be a valuable therapeutic measure in this patient population.
Hypothesis about the potential effect of the statins preventing or inhibiting the development of high risk CaP needs to be proven applying specific clinical trials designed for this purpose. There isn't conclusive data that demonstrate that statins lower the risk of development of potentially lethal high grade CaP.